Anika Therapeutics (ANIK) Gross Margin (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Gross Margin of 65.15% for Q2 2026, up 1425.0% year-over-year from 4.27% in Q2 2025, and up 1.55% quarter-over-quarter from 64.15% in Q1 2026.
Anika Therapeutics (ANIK) Gross Margin (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Gross Margin for 17 consecutive years, with 65.15% the latest figure, recorded in Q2 2026.
- In Q2 2026, Gross Margin rose 1425.0% year-over-year to 65.15%; the TTM figure through Jun 2026 stood at 62.16% (up 492.0% YoY), while the FY2025 annual figure was 56.56%, down 682.0% from the prior year.
- Gross Margin advanced to 65.15% in Q2 2026 per ANIK's latest filing, from 64.15% in the prior quarter.
- Across five years, Gross Margin topped out at 66.69% in Q2 2024 and bottomed at 199.14% in Q4 2023.
- Historically, Gross Margin has averaged 35.47% across 5 years, with a median of 60.2% in 2023.
- Annual changes were most pronounced in 2022 — Gross Margin sank 18607 bps — and 2024, when it surged 25510 bps.
- Anika Therapeutics' Gross Margin stood at 135.45% in 2022, then tumbled by 47 bps to 199.14% in 2023, then surged by 128 bps to 55.96% in 2024, then grew by 12 bps to 62.65% in 2025, then grew by 4 bps to 65.15% in 2026.
- Business Quant data shows ANIK's Gross Margin at 65.15% in Q2 2026, 64.15% in Q1 2026, and 62.65% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Anika Therapeutics | 284.33 Mn | 245.92 Mn | 21.24 Mn | 65.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 65.15% |
| Mar 31, 2026 | 64.15% |
| Dec 31, 2025 | 62.65% |
| Sep 30, 2025 | 56.02% |
| Jun 30, 2025 | 50.90% |
| Mar 31, 2025 | 56.10% |
| Dec 31, 2024 | 55.96% |
| Sep 30, 2024 | 65.66% |
| Jun 30, 2024 | 66.69% |
| Mar 31, 2024 | 65.38% |
| Dec 31, 2023 | -199.14% |
| Sep 30, 2023 | 60.16% |
| Jun 30, 2023 | 65.40% |
| Mar 31, 2023 | 60.23% |
| Dec 31, 2022 | -135.45% |
| Sep 30, 2022 | 56.57% |
| Jun 30, 2022 | 62.69% |
| Mar 31, 2022 | 59.42% |
| Dec 31, 2021 | 50.62% |
| Sep 30, 2021 | 58.23% |